Sort
48,018 grants matching “immunotherapy”
T cell repertoire of graft-versus-host disease and graft-versus-tumor effects
$365,317Robert Korngold · Hackensack University Medical Center · R01 · FY2013 · CA
Epigenetically Engineered Mouse Model for Lung Cancer Therapy
$365,308Lanlan Shen · Baylor College Of Medicine · R01 · FY2021 · CA
Targeting Wnt signaling in therapy-resistant ovarian cancer
$365,281Benjamin G Bitler · University Of Colorado Denver · R37 · FY2021 · CA
Evaluation of image-guided, conformal, high-dose intraoperative radiation therapy (Precision Breast IORT) for early stage breast cancer
$365,266Shayna Lefrak Showalter · University Of Virginia · R01 · FY2019 · CA
Ricin-Mechanism, Transition State and Inhibitor Design
$365,254Vern L. Schramm · Albert Einstein College Of Medicine · R01 · FY2008 · CA
The Genetics of Post-Transplant Relapse in Myeloid Malignancy
$365,200Jerald P Radich · Fred Hutchinson Cancer Research Center · R01 · FY2017 · CA
The Genetics of Post-Transplant Relapse in Myeloid Malignancy
$365,200Jerald P Radich · Fred Hutchinson Cancer Research Center · R01 · FY2016 · CA
The Genetics of Post-Transplant Relapse in Myeloid Malignancy
$365,200Jerald P Radich · Fred Hutchinson Cancer Research Center · R01 · FY2015 · CA
The Genetics of Post-Transplant Relapse in Myeloid Malignancy
$365,200Jerald P Radich · Fred Hutchinson Cancer Research Center · R01 · FY2013 · CA
Microbial- based targeting of major extracellular matrix components for improved therapy of pancreatic cancer
$365,200Edwin Manuel · Beckman Research Institute/City Of Hope · R01 · FY2022 · CA
BLIMP-1 mediated regulation of CD8+ TIL
$365,178Timothy N Bullock · University Of Virginia · R01 · FY2015 · CA
OSTEOCLASTS AND BONE CANCER
$365,168University Of Minnesota Twin Cities · R01 · FY2002 · AR
Dual-pronged nano-drug delivery using plant virus-like particles
$365,157Nicole Franziska Steinmetz · University Of California, San Diego · R01 · FY2023 · CA
STING Activating Synthetic Nanovaccine for HPV-Induced Cancers
$365,135Jinming Gao · Ut Southwestern Medical Center · R01 · FY2019 · CA
CALGB
$365,117Ohio State University · U10 · FY2002 · CA
Type I Interferon Pathway in Pancreatic Adenocarcinoma
$365,086Serge Y Fuchs · University Of Pennsylvania · R01 · FY2021 · CA
Project 2: Analyses of the human GBM microenvironment form clinical trial specimens treated with the oncolytic HSV, rQNestin34v.2
$365,084E. Antonio Chiocca · Brigham And Women'S Hospital · P01 · FY2025 · CA
Exploiting dual-TCR for rescue of CD8 T cell tolerance in adoptive immunotherapy
$365,063Ryan M Teague · Saint Louis University · R01 · FY2011 · AI
Exploiting dual-TCR for rescue of CD8 T cell tolerance in adoptive immunotherapy
$365,063Ryan M Teague · Saint Louis University · R01 · FY2014 · AI
Exploiting dual-TCR for rescue of CD8 T cell tolerance in adoptive immunotherapy
$365,063Ryan M Teague · Saint Louis University · R01 · FY2012 · AI
Cancer Center Support Grant
$365,042Tim E Byers · University Of Colorado Denver · P30 · FY2009 · CA
MicroRNA-15a/16-mediated cytokine/chemokine reprogramming in Kupffer cells prevents the development of hepatocellular carcinoma
$365,037Guisheng Song · University Of Minnesota · R01 · FY2023 · CA
Actively engaging NK cells during virotherapy to induce neoantigen-specific antitumor immunity
$365,032Xiaoliu Zhang · University Of Houston · R01 · FY2024 · CA
Role of iNKT Cells in Autoimmunity and Atherosclerosis
$365,025Amy S Major · Vanderbilt University · R01 · FY2007 · HL
LncRNA EPIC1 induces immunotherapy resistance by activating EZH2 in breast cancer
$365,009Da Yang · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · CA